Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

141.11 -1.87 (-1.31%)
Streaming Delayed Price Updated: 10:03 AM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 821,826
Open 141.34
Bid (Size) 141.06 (1)
Ask (Size) 141.11 (1)
Prev. Close 142.98
Today's Range 140.84 - 141.47
52wk Range 75.56 - 148.15
Shares Outstanding N/A
Dividend Yield 1.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
The company is on deck to rival Biogen and Eisai's Leqembi. 
Via Investor's Business Daily
Why Novo Nordisk Stock Is Slipping Today
President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people." 
Via The Motley Fool

Performance

YTD
+38.19%
+38.19%
1 Month
+4.05%
+4.05%
3 Month
+11.58%
+11.58%
6 Month
+38.19%
+38.19%
1 Year
+77.02%
+77.02%

More News

Read More
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
Via Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
Via Chartmill
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Via MarketBeat
Exposures Product Safety
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Via Talk Markets
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Via The Motley Fool
This Is Massive News for Eli Lilly Investors
Via The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
Via Investor's Business Daily
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Via Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
Via Benzinga
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Via Benzinga
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Via Benzinga
Topics Fraud Supply Chain
Exposures Legal Supply Chain
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Via Benzinga
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.